BioLineRx Valuation
| BLRX Stock | USD 3.01 0.04 1.31% |
At this time, the firm appears to be undervalued. BioLineRx shows a prevailing Real Value of $8.63 per share. The current price of the firm is $3.01. Our model approximates the value of BioLineRx from analyzing the firm fundamentals such as Profit Margin of (0.45) %, return on equity of -0.46, and Current Valuation of (433.96 K) as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting BioLineRx's valuation include:
Price Book 0.6794 | Enterprise Value | Enterprise Value Ebitda 1.1052 | Price Sales 1.1242 | Forward PE 93.4579 |
Undervalued
Today
Please note that BioLineRx's price fluctuation is somewhat reliable at this time. Calculation of the real value of BioLineRx is based on 3 months time horizon. Increasing BioLineRx's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BioLineRx is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioLineRx Stock. However, BioLineRx's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.01 | Real 8.63 | Target 26.0 | Hype 3.0 | Naive 3.02 |
The intrinsic value of BioLineRx's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BioLineRx's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of BioLineRx helps investors to forecast how BioLineRx stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioLineRx more accurately as focusing exclusively on BioLineRx's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use BioLineRx's intrinsic value based on its ongoing forecasts of BioLineRx's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against BioLineRx's closest peers.
BioLineRx Cash |
|
BioLineRx Total Value Analysis
BioLineRx is currently projected to have valuation of (433.96 K) with market capitalization of 15.18 M, debt of 15.04 M, and cash on hands of 43.15 M. The negative valuation of BioLineRx may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the BioLineRx fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(433.96 K) | 15.18 M | 15.04 M | 43.15 M |
BioLineRx Investor Information
The company has price-to-book (P/B) ratio of 0.68. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioLineRx has Price/Earnings To Growth (PEG) ratio of 0.2. The entity recorded a loss per share of 6.0. The firm last dividend was issued on the 15th of July 2019. BioLineRx had 1:40 split on the 30th of January 2025. Based on the key measurements obtained from BioLineRx's financial statements, BioLineRx is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.BioLineRx Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BioLineRx has an asset utilization ratio of 74.38 percent. This suggests that the Company is making $0.74 for each dollar of assets. An increasing asset utilization means that BioLineRx is more efficient with each dollar of assets it utilizes for everyday operations.BioLineRx Profitability Analysis
Based on the key profitability measurements obtained from BioLineRx's financial statements, BioLineRx may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess BioLineRx's ability to earn profits and add value for shareholders.Net Loss | First Reported 2009-12-31 | Previous Quarter -3.9 M | Current Value -5.8 M | Quarterly Volatility 5 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.62 | 0.78 |
|
|
For BioLineRx profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioLineRx to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioLineRx utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioLineRx's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioLineRx over time as well as its relative position and ranking within its peers.
BioLineRx Earnings per Share Projection vs Actual
The next projected EPS of BioLineRx is estimated to be -0.19875 with future projections ranging from a low of -0.24 to a high of -0.1575. BioLineRx's most recent 12-month trailing earnings per share (EPS TTM) is at -6.0. Please be aware that the consensus of earnings estimates for BioLineRx is based on EPS before non-recurring items and includes expenses related to employee stock options.BioLineRx Earnings Estimation Breakdown
The calculation of BioLineRx's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of BioLineRx is estimated to be -0.19875 with the future projection ranging from a low of -0.24 to a high of -0.1575. Please be aware that this consensus of annual earnings estimates for BioLineRx is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.24 Lowest | Expected EPS | -0.16 Highest |
BioLineRx Earnings Projection Consensus
Suppose the current estimates of BioLineRx's value are higher than the current market price of the BioLineRx stock. In this case, investors may conclude that BioLineRx is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and BioLineRx's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 2 | 49.0% | -0.2259 | -0.19875 | -6.0 |
BioLineRx Ownership Allocation
The market capitalization of BioLineRx is $15.18 Million. BioLineRx shows 3.99 percent of its outstanding shares held by insiders and 1.07 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.BioLineRx Profitability Analysis
The company reported the previous year's revenue of 28.94 M. Net Loss for the year was (9.22 M) with profit before overhead, payroll, taxes, and interest of 10.23 M.About BioLineRx Valuation
Our relative valuation model uses a comparative analysis of BioLineRx. We calculate exposure to BioLineRx's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioLineRx's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 17.7 M | 18.6 M | |
| Pretax Profit Margin | (0.37) | (0.38) | |
| Operating Profit Margin | (0.81) | (0.85) | |
| Net Loss | (0.37) | (0.38) | |
| Gross Profit Margin | 0.78 | 0.62 |
BioLineRx Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 79.9 M | |
| Forward Price Earnings | 93.4579 |
BioLineRx Current Valuation Indicators
Valuation refers to the process of determining the present value of BioLineRx and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value BioLineRx we look at many different elements of the entity such as BioLineRx's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as BioLineRx, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use BioLineRx's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes BioLineRx's worth.Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.